Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium Glycididazole with Preoperative Chemoradiotherapy for Esophageal Squamous Cell Carcinoma
NCT02721550Phase 4
Key facts
- Status
- Terminated
- Start
- Aug 2016
- Primary completion
- Jun 2018
- Countries
- 1
- Sponsor
- Shandong Cancer Hospital
- Modality
- Small Molecules
- Drugs
- sodium glycididazole
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC)
01
Overview
Phase 4, open-label, single-arm trial of sodium glycididazole in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Shandong Cancer Hospital. Primary endpoint: pathologic Complete Response at 1 month. Started Aug 2016; status: terminated.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Sodium Glycididazole + Chemoradiotherapy
Sodium Glycididazole combined with preoperative concurrent chemoradiotherapy (Paclitaxel/Cisplatin, Docetaxel/Cisplatin, Nedaplatin, or 5-FU based regimens) followed by surgery.
03
Who it enrols
Patients with resectable thoracic ESCC (T2-3, N0-1, M0), ECOG 0-1, and adequate organ function. Excludes prior anti-cancer treatment, distant metastasis, and other malignancies.
04
Endpoints
Primary
pathologic Complete Response
Secondary
Overall Survival
Disease-Free Survival
Beyond the preview
Go deeper on NCT02721550.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02721550.